UCB Q3 in line as Keppra holds
This article was originally published in Scrip
In its interim report for the second half of the year, Belgium's UCB said its third quarter was in line with expectations, with revenue declining as a consequence to generic Keppra (levetiracetam) competition in the US. However, this was partially off-set by the strong performance of Keppra in Europe, which continued to show double-digit sales growth and by the similarly strong growth of Xyzal (levocetirizine) in the US and of Zyrtec (cetirizine) in Japan.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.